Yunhe Gao, Kecheng Zhang, Hongqing Xi, Aizhen Cai, Xiaosong Wu, Jianxin Cui, Jiyang Li, Zhi Qiao, Bo Wei, Lin Chen. Chinese People’s Liberation Army of General Hospital
Background: Circulating tumor DNA (ctDNA) has offered a minimally invasive approach for detection and measurement of gastric cancer (GC). However, its diagnostic and prognostic value in GC still remains unclear.
Methods: We searched Pubmed, Embase, Cochrane Library and Web of Science databases for literature published up until June 2016. Diagnostic accuracy variables were pooled by the Meta-Disc software. Engauge Digitizer and Stata software were applied for prognostic data extraction and analysis.
Results: A total of 15 studies comprising 1277 GC patients met our inclusion criteria. The pooled sensitivity and specificity were 0.58 (95% confidence intervals (CI) 0.55–0.61) and 0.94 (95%CI 0.92–0.96), respectively. The AUSROC (area under SROC) curve was 0.91 (95%CI 0.85–0.97). Moreover, there was also a statistically significant association between the presence of ctDNA and worse overall survival (HR 1.56, 95%CI 1.10–2.20, p=0.012), as well as disease-free survival (HR 6.221, 95%CI 2.486–15.567, p=0.000).
Conclusions: Our meta-analysis indicates the detection of ctDNA is significantly associated with poor prognosis of GC patients, with high specificity and relatively moderate sensitivity.
Presented at the SAGES 2017 Annual Meeting in Houston, TX.
Abstract ID: 78872
Program Number: P075
Presentation Session: Poster (Non CME)
Presentation Type: Poster